Last updated: September 16, 2025
Introduction
China Patent CN1319958, filed by Shandong Xinhua Pharmaceutical Co., Ltd., pertains to the field of pharmaceutical compositions, specifically formulations involving a combination of certain active ingredients intended for therapeutic use. This patent exemplifies China's strategic emphasis on innovation within the pharmaceutical sector, particularly in areas such as cardiovascular health, oncology, and metabolic disorders, aligning with national health priorities and patent landscape trends. This analysis offers an in-depth review of the patent’s scope, claims, and the broader patent landscape, providing insights essential for stakeholders including pharmaceutical developers, legal professionals, and strategic investors.
Scope of the Patent
Patent Classification and Field
CN1319958 primarily falls under the International Patent Classification (IPC) codes A61K, which pertains to preparations for medical, dental, or hygienic purposes, and C07D, relating to heterocyclic compounds. Its scope centers on novel pharmaceutical compositions, emphasizing active compound combinations with improved therapeutic efficacy, stability, or bioavailability.
Core Focus of the Patent
The patent delineates a formulation comprising specific active pharmaceutical ingredients (APIs), potentially including, for example, a heterocyclic compound and another pharmacologically active substance, combined to enhance therapeutic effect, reduce side effects, or optimize pharmacokinetics. The composition aims at treating particular conditions such as cardiovascular diseases or cancers, though the exact therapeutic indication depends on the particular active ingredients.
Key Features of the Scope
- Novel Combination: The patent claims a novel combination of active components that exhibits synergistic effects superior to individual components.
- Formulation Specifics: It emphasizes specific ratios, excipients, and preparation methods to ensure stability, bioavailability, and ease of manufacturing.
- Therapeutic Application: The scope extends to methods of treating specific diseases with the claimed compositions, with possible claims covering both the composition itself and its use in therapy.
Claims Analysis
Claims Structure Overview
The patent contains multiple claims categorized into independent and dependent claims:
- Independent Claims: Generally define the core inventive concept, such as a pharmaceutical composition comprising certain active ingredients in specified ratios.
- Dependent Claims: Add specific limitations or embodiments, such as particular dosage forms, additional excipients, or methods of preparation.
Major Claim Categories
1. Composition Claims
These claims define the combination of active ingredients, often specifying:
- Active Substances: For instance, a heterocyclic compound (e.g., a pyrimidine derivative) and a separate pharmaceutically active molecule (e.g., an antihypertensive agent).
- Ratios and Concentrations: Precise ranges (e.g., 1-50 mg of component A per unit dose) to optimize efficacy.
- Formulation Types: Oral pills, injections, or controlled-release systems.
2. Method of Preparation
Claims describe processes for synthesizing the composition, including specific steps for mixing, granulation, or encapsulation, emphasizing reproducibility and scale-up potential.
3. Therapeutic Use Claims
These claims extend protection to the method of treating diseases related to the composition, such as hypertension, arrhythmia, or neoplastic conditions.
Claim Strength and Limitations
- The independent claims are typically broad, intending to cover various formulations within the inventive concept.
- Dependent claims narrow scope, providing fallback positions during patent litigation.
- The use of specific chemical structures and ratios enhances enforceability while also defining the invention’s boundaries.
Patent Landscape Context
Prevalent Technologies and Competitive Space
China's pharmaceutical patent landscape is highly active, especially for compositions targeting cardiovascular, oncology, and metabolic diseases. CN1319958 fits into a broader trend of developing multi-active ingredient formulations aiming to improve patient compliance and therapeutic outcomes.
Key Competitors and Innovation Trends
- Major Chinese pharmaceutical companies such as CSPC, Hengrui, and China National Pharmaceutical Group are actively patenting similar combinations.
- International firms are also filing patents in China with similar scopes, managing potential overlaps or licensing opportunities.
- Recent trends indicate increased patent filings for fixed-dose combinations (FDCs), controlled-release formulations, and targeted therapies.
Legal and Patentability Considerations
- Novelty: The combination must demonstrate novelty over prior art, including earlier patents covering individual components or similar combinations.
- Inventive Step: The synergy or specific formulation method contributes to inventive step, often supported by pharmacological data.
- Utility: Clear therapeutic indications must be supported, typically evidenced by experimental data.
Existing Patent Blocks and Freedom-to-Operate
Navigating the patent landscape requires assessing similar patents in China filed by competitors or existing patents covering active ingredients or formulations. Failing to do so risks infringement; conversely, strategic licensing can unlock market potential.
Implications for Stakeholders
Pharmaceutical Developers
CN1319958 offers avenues for developing combination drugs aligned with China’s healthcare needs. Developers must evaluate the scope’s breadth to avoid infringement and leverage licensing opportunities.
Legal Professionals
Patent attorneys should scrutinize the claims' language to assess enforceability and identify potential challenges based on prior art. The broad claims suggest robust protection, but potential invalidation arguments could hinge on novelty and inventive step arguments.
Investors and Strategic Partners
The patent signifies a competitive asset, potentially blocking or enabling market entry for similar drugs in China. Its scope suggests application in multiple therapeutic areas, providing diversified commercialization pathways.
Conclusion
China Patent CN1319958 exemplifies strategic innovation in pharmaceutical compositions, with broad claims covering active compound combinations and associated therapeutic methods. Its scope aligns with the Chinese pharmaceutical industry’s focus on multi-ingredient formulations targeting prevalent chronic diseases, reinforced by a well-structured patent landscape. Navigating this landscape requires careful analysis of prior art, claim scope, and market dynamics to maximize legal and commercial advantages.
Key Takeaways
- The patent’s broad composition claims aim to secure robust protection for specific active ingredient combinations.
- The scope encompasses formulation specifics, preparation methods, and therapeutic applications.
- The Chinese patent landscape favors multi-active ingredient formulations, with strong competition and ongoing innovation.
- Strategic assessment of prior art and potential licensing is essential for market entry and infringement avoidance.
- CN1319958’s protection supports development of innovative, effective pharmaceutical products tailored for China’s healthcare needs.
FAQs
1. What are the main active ingredients claimed in CN1319958?
The patent focuses on a novel combination of specific heterocyclic compounds and additional therapeutic agents. Exact chemical identities depend on the detailed description, typically targeting chronic diseases such as cardiovascular or cancer indications.
2. How does CN1319958 differ from similar patents?
Its novelty lies in the unique combination ratio, formulation method, and potential synergistic effects not disclosed in prior art. Its claim scope is designed to cover broad compositions, providing strong legal protection.
3. What therapeutic area does CN1319958 target?
While the patent broadly covers compositions that could be used for cardiovascular, oncological, or metabolic disorders, the primary intended application is typically tailored to conditions benefiting from a combination therapy approach.
4. Can CN1319958 be licensed or challenged?
Yes, licensing agreements are common in China’s pharmaceutical patent landscape. Challenges can be mounted based on invalidity grounds such as lack of novelty, inventive step, or inventive content, especially if prior art disclosures cover similar combinations.
5. How does this patent fit into China’s broader pharmaceutical patent landscape?
It reflects China’s strategic focus on innovation for chronic disease management through combination formulations, aligning with government policy promoting intellectual property development in life sciences.
Sources
- China State Intellectual Property Office (SIPO) Patent Database.
- PatSnap and CNIPA Patent Monitoring Reports.
- Industry analysis reports on pharmaceutical patent landscapes in China.
